Tenaya Therapeutics announced positive preclinical data for TN-201, its gene therapy candidate for MYBPC3-associated hypertrophic cardiomyopathy (HCM), published in •Nature Communications•. The therapy, delivered via a single intravenous infusion, aims to increase MyBP-C protein levels, addressing the underlying cause of this genetic heart condition. Preclinical studies show TN-201 reversed left ventricular hypertrophy, a key indicator of HCM, in mice models.
This research holds significant promise for patients with MYBPC3-associated HCM, a prevalent and severe form of the disease with limited treatment options. Current treatments primarily manage symptoms, while TN-201 targets the root genetic cause, potentially offering a more effective and durable solution. The demonstrated reversal of left ventricular hypertrophy suggests the potential not just to halt disease progression but to improve heart function and potentially enhance long-term outcomes for patients.
In preclinical studies, TN-201 achieved dose-dependent increases in MyBP-C protein and improved multiple cardiac function parameters. A low dose of 1×10^13 vg/kg proved effective, and notably, protein levels did not exceed wild-type levels even with higher RNA overexpression, suggesting a positive safety profile. The therapy also demonstrated durability, with effects lasting up to 20 months post-treatment in mice. The ongoing Phase 1b/2 MyPEAK-1 clinical trial is evaluating TN-201 at doses of 3×10^13 vg/kg and 6×10^13 vg/kg, aligning with the effective preclinical dosages.
The positive preclinical data strengthens the rationale for TN-201’s clinical development and underscores its potential to transform the HCM treatment landscape. The findings suggest that gene therapy could address the underlying genetic defect driving this disease, offering a potential cure for patients with MYBPC3-associated HCM. The upcoming release of clinical trial data will be crucial in further validating this approach and determining its efficacy and safety in humans.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
